PHATHOM PHARMACEUTICALS, INC. Financials Phathom Pharmaceuticals, Inc.
Equities
PHAT
US71722W1071
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.5 USD | +1.94% |
|
-0.38% | +15.01% |
| May. 09 | Transcript : Phathom Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
| May. 09 | Phathom Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 763.8 | 935.7 | 595.5 | 461.6 | 522.7 | 614.5 | - | - |
| Enterprise Value (EV) 1 | 542.8 | 697.2 | 501.9 | 402.2 | 279.9 | 438.6 | 541.2 | 743.8 |
| P/E ratio | -2.73 x | -8.56 x | -5.06 x | -2.22 x | -2.32 x | -2 x | -2.82 x | -6.51 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | 766 x | 14.6 x | 3.72 x | 1.7 x |
| EV / Revenue | - | - | - | - | 410 x | 10.4 x | 3.27 x | 2.06 x |
| EV / EBITDA | -5.11 x | -5.56 x | -3.73 x | -2.34 x | -1.68 x | -1.68 x | -2.26 x | -6.45 x |
| EV / FCF | -14.8 x | -9.86 x | -3.09 x | -2.73 x | -2.01 x | -1.66 x | -2.71 x | -5.01 x |
| FCF Yield | -6.75% | -10.1% | -32.3% | -36.7% | -49.7% | -60.4% | -36.9% | -20% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 24,527 | 28,166 | 30,276 | 41,144 | 57,253 | 58,524 | - | - |
| Reference price 2 | 31.14 | 33.22 | 19.67 | 11.22 | 9.130 | 10.50 | 10.50 | 10.50 |
| Announcement Date | 3/19/20 | 3/30/21 | 3/1/22 | 2/28/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 0.682 | 42.22 | 165.4 | 360.8 |
| EBITDA 1 | -106.2 | -125.3 | -134.6 | -171.8 | -166.7 | -261.6 | -239.6 | -115.3 |
| EBIT 1 | -106.2 | -125.7 | -135.1 | -172.4 | -167.3 | -266.6 | -214 | -83.16 |
| Operating Margin | - | - | - | - | -24,532.55% | -631.41% | -129.42% | -23.05% |
| Earnings before Tax (EBT) 1 | -255.1 | -129.1 | -143.9 | -197.7 | -201.6 | -318.1 | -257.8 | -132.7 |
| Net income 1 | -255.1 | -129.1 | -143.9 | -197.7 | -201.6 | -318.1 | -257.8 | -132.7 |
| Net margin | - | - | - | - | -29,558.94% | -753.52% | -155.91% | -36.79% |
| EPS 2 | -11.41 | -3.880 | -3.890 | -5.050 | -3.930 | -5.254 | -3.725 | -1.614 |
| Free Cash Flow 1 | -36.64 | -70.73 | -162.4 | -147.6 | -139.2 | -265 | -199.6 | -148.6 |
| FCF margin | - | - | - | - | -20,412.61% | -627.71% | -120.71% | -41.18% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/19/20 | 3/30/21 | 3/1/22 | 2/28/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | 0.682 | 1.912 | 5.551 | 11.3 | 22.88 | 29.01 | 42.2 |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | - | -62.66 | -60.96 | -56.77 | - | - |
| EBIT 1 | -33.04 | -37.91 | -45.36 | -42.53 | -46.64 | -30.08 | -31.7 | -35.66 | -69.87 | -69.95 | -69.98 | -68.18 | -61.86 | -59.67 | -49.1 |
| Operating Margin | - | - | - | - | - | - | - | - | -10,245.45% | -3,658.68% | -1,260.63% | -603.25% | -270.4% | -205.65% | -116.35% |
| Earnings before Tax (EBT) 1 | -35.83 | -40.66 | -50.92 | -51.09 | -55.05 | -37.81 | -40.96 | -43.24 | -79.57 | -82.85 | -78.22 | -76.13 | -68.91 | -67.8 | -61.9 |
| Net income 1 | -35.83 | -40.66 | -50.92 | -51.09 | -55.05 | -37.81 | -40.96 | -43.24 | -79.57 | -82.85 | -78.22 | -76.13 | -68.91 | -67.8 | -61.9 |
| Net margin | - | - | - | - | - | - | - | - | -11,667.01% | -4,333.26% | -1,409.05% | -673.61% | -301.23% | -233.68% | -146.68% |
| EPS 2 | -0.9500 | -1.070 | -1.330 | -1.320 | -1.330 | -0.8900 | -0.8400 | -0.7600 | -1.390 | -1.420 | -1.400 | -1.368 | -1.108 | -1.075 | -1.060 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/1/22 | 5/10/22 | 8/2/22 | 11/8/22 | 2/28/23 | 5/10/23 | 8/10/23 | 11/9/23 | 3/7/24 | 5/9/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | 129 |
| Net Cash position 1 | 221 | 238 | 93.6 | 59.4 | 243 | 176 | 73.3 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | -1.121 x |
| Free Cash Flow 1 | -36.6 | -70.7 | -162 | -148 | -139 | -265 | -200 | -149 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share 2 | - | - | - | - | - | -3.810 | -1.100 | -0.6400 |
| Capex 1 | 0.13 | 1.04 | 0.33 | 1.04 | 1.63 | 1.06 | 2.49 | 2.4 |
| Capex / Sales | - | - | - | - | 239.59% | 2.52% | 1.51% | 0.66% |
| Announcement Date | 3/19/20 | 3/30/21 | 3/1/22 | 2/28/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
10.5
USD
Average target price
22.29
USD
Spread / Average Target
+112.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.01% | 615M | |
| +67.53% | 63.85B | |
| -0.77% | 41.83B | |
| +45.66% | 40.65B | |
| -10.72% | 27.12B | |
| +13.30% | 26.52B | |
| -22.79% | 18.69B | |
| +4.70% | 12.73B | |
| +24.10% | 12.11B | |
| +27.41% | 12.07B |
- Stock Market
- Equities
- PHAT Stock
- Financials Phathom Pharmaceuticals, Inc.
